Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Messing With Success”: CMS’ Case For Changing Part D – And How Data Sharing May Help

This article was originally published in RPM Report

Executive Summary

CMS is backing down from some of the more controversial ideas in what would have been a sweeping update to the rules for Part D, after facing broad opposition. However, the bigger message from the proposed rule is that CMS’ isn’t going to stop trying to improve Part D – and one relatively minor provision that is moving forward may recruit more outsiders to that cause.

You may also be interested in...



Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start

The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.

CMS Wades Into the Opioid Debate

Reducing prescription drug abuse is a high priority item for several key legislators and for the Obama Administration. Proposed new rules for Medicare drug plan sponsors might help—but they also underscore the growing tension among the many different stakeholders in the pharmaceutical supply chain.

Is The US FDA At A Tipping Point?

Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.

Topics

UsernamePublicRestriction

Register

PS079694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel